BTG PLC Directorate Change (3807W)

TIDMBTG

RNS Number : 3807W

BTG PLC

14 November 2017

BTG plc: Directorate change - Chief Financial Officer

London, UK, 14 November 2017: BTG plc (LSE: BTG), the global specialist healthcare company, announces that after 10 years as Chief Financial Officer (CFO) at BTG, Rolf Soderstrom is to step down as an Executive Director of the Company. The Board intends to appoint Duncan Kennedy to succeed Rolf as CFO on 1 January 2018. Rolf will remain with the Company until completion of a smooth handover to Duncan, which is expected to be concluded by 31 March 2018.

Duncan currently leads BTG's Interventional Oncology business, a role he has held since May 2015. He joined BTG in December 2005 as Group Financial Controller and became a member of the Leadership Team in April 2012 when he was appointed Group Director of Finance, with responsibility for managing the global finance function and supporting the CFO. Prior to joining BTG, Duncan spent six years in the group finance function of Wembley plc. Duncan qualified as a Chartered Accountant at Arthur Andersen and holds a BSc in Mathematics from Durham University.

"The Board is grateful to Rolf for his many significant contributions to BTG since joining the Company in 2008 following the acquisition of Protherics, and we wish him well for the future," said Garry Watts, BTG's Chairman. "We are also delighted to appoint Duncan as CFO, and look forward to continuing working with him in his new role as we further expand BTG's business."

Louise Makin, BTG's CEO, commented: "I would like to add my personal thanks to Rolf for all his support over the past 10 years, while we have worked together to build the company. I also look forward to working with Duncan as our new CFO as we continue to take BTG forwards."

There are no further disclosures to be made under rule 9.6.13 of the Listing Rules.

For further information contact:

BTG

Andy Burrows, VP Corporate & Investor Relations

[phone]; Mobile: [phone]

Stuart Hunt, Investor Relations Manager

[phone]; Mobile: [phone]

Chris Sampson, Corporate Communications Director

[phone]; Mobile: [phone]

FTI Consulting

Ben Atwell/Simon Conway

[phone]

About BTG

BTG is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: btgplc.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOABXLLFDFFLFBQ

(END) Dow Jones Newswires

November 14, 2017 02:01 ET (07:01 GMT)